Dimeric IgA is a specific biomarker of recent SARS-CoV-2 infection
Drummer, H. E.; Van, H.; Klock, E.; Zheng, S.; Wei, Z.; Boo, I.; Center, R. J.; Li, F.; Bhat, P.; Ffrench, R.; Lau, J. S. Y.; McMahon, J.; Laeyendecker, O.; Fernandez, R. E.; Manabe, Y. C.; Klein, S. L.; Quinn, T. C.; Anderson, D. A.
Show abstract
Current tests for SARS-CoV-2 antibodies (IgG, IgM, IgA) cannot differentiate recent and past infections. We describe a point of care, lateral flow assay for SARS-CoV-2 dIgA based on the highly selective binding of dIgA to a chimeric form of secretory component (CSC), that distinguishes dIgA from monomeric IgA. Detection of specific dIgA uses a complex of biotinylated SARS-CoV-2 receptor binding domain and streptavidin-colloidal gold. SARS-CoV-2-specific dIgA was measured both in 112 cross-sectional samples and a longitudinal panel of 362 plasma samples from 45 patients with PCR-confirmed SARS-CoV-2 infection, and 193 discrete pre-COVID-19 or PCR-negative patient samples. The assay demonstrated 100% sensitivity from 11 days post-symptom onset, and a specificity of 98.2%. With an estimated half-life of 6.3 days, dIgA provides a unique biomarker for the detection of recent SARS-CoV-2 infections with potential to enhance diagnosis and management of COVID-19 at point-of-care.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Reduced serum neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay 96%
- Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays 95%
- Distinct SARS-CoV-2 Antibody Reactivity Patterns in Coronavirus Convalescent Plasma Revealed by a Coronavirus Antigen Microarray 94%
Similar papers in this journal
- Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination 96%
- Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection 96%
- Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples 95%
Similar papers in this journal
- A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination 96%
- Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma 94%
- Previous SARS-CoV-2 infection or a third dose of vaccine elicited cross-variant neutralizing antibodies in vaccinated solid organ transplant recipients 93%
Similar papers in this journal
- Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens 96%
- A hemagglutination-based, semi-quantitative test for point-of-care determination of SARS-CoV-2 antibody levels 96%
- Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays in infected, recovered, and vaccinated groups 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.